TY - JOUR
T1 - Vaporized D-limonene selectively mitigates the acute anxiogenic effects of Δ9-tetrahydrocannabinol in healthy adults who intermittently use cannabis
AU - Spindle, Tory R.
AU - Zamarripa, C. Austin
AU - Russo, Ethan
AU - Pollak, Lauren
AU - Bigelow, George
AU - Ward, Alexandra M.
AU - Tompson, Bridget
AU - Sempio, Cristina
AU - Shokati, Touraj
AU - Klawitter, Jost
AU - Christians, Uwe
AU - Vandrey, Ryan
N1 - Publisher Copyright:
© 2024 Elsevier B.V.
PY - 2024/4/1
Y1 - 2024/4/1
N2 - Background: Cannabis contains hundreds of chemical constituents beyond delta-9-tetrahydrocannabinol (THC), which is believed to drive most of its acute pharmacodynamic effects. The entourage effect theory asserts that non-THC constituents can impact acute cannabis effects, but few empirical studies have systematically evaluated this theory in humans. This study assessed whether the cannabis terpenoid D-limonene mitigates the acute anxiogenic effects of THC. Methods: Twenty healthy adults completed nine, double-blind outpatient sessions in which they inhaled vaporized THC alone (15 mg or 30 mg), D-limonene alone (1 mg or 5 mg), the same doses of THC and D-limonene together, or placebo; a subset of participants (n=12) completed a tenth session in which 30 mg THC+15 mg D-limonene was administered. Outcomes included subjective drug effects, cognitive/psychomotor performance, vital signs, and plasma THC and D-limonene concentrations. Results: When d-limonene was administered alone, pharmacodynamic outcomes did not differ from placebo. Administration of 15 mg and 30 mg THC alone produced subjective, cognitive, and physiological effects typical of acute cannabis exposure. Ratings of anxiety-like subjective effects qualitatively decreased as D-limonene dose increased and concurrent administration of 30 mg THC+15 mg D-limonene significantly reduced ratings of “anxious/nervous” and “paranoid” compared with 30 mg THC alone. Other pharmacodynamic effects were unchanged by D-limonene. D-limonene plasma concentrations were dose orderly, and concurrent administration of D-limonene did not alter THC pharmacokinetics. Conclusions: D-limonene selectively attenuated THC-induced anxiogenic effects, suggesting this terpenoid could increase the therapeutic index of THC. Future research should determine whether this effect extends to oral dose formulations and evaluate the interactions between other cannabis terpenoids or cannabinoids and THC.
AB - Background: Cannabis contains hundreds of chemical constituents beyond delta-9-tetrahydrocannabinol (THC), which is believed to drive most of its acute pharmacodynamic effects. The entourage effect theory asserts that non-THC constituents can impact acute cannabis effects, but few empirical studies have systematically evaluated this theory in humans. This study assessed whether the cannabis terpenoid D-limonene mitigates the acute anxiogenic effects of THC. Methods: Twenty healthy adults completed nine, double-blind outpatient sessions in which they inhaled vaporized THC alone (15 mg or 30 mg), D-limonene alone (1 mg or 5 mg), the same doses of THC and D-limonene together, or placebo; a subset of participants (n=12) completed a tenth session in which 30 mg THC+15 mg D-limonene was administered. Outcomes included subjective drug effects, cognitive/psychomotor performance, vital signs, and plasma THC and D-limonene concentrations. Results: When d-limonene was administered alone, pharmacodynamic outcomes did not differ from placebo. Administration of 15 mg and 30 mg THC alone produced subjective, cognitive, and physiological effects typical of acute cannabis exposure. Ratings of anxiety-like subjective effects qualitatively decreased as D-limonene dose increased and concurrent administration of 30 mg THC+15 mg D-limonene significantly reduced ratings of “anxious/nervous” and “paranoid” compared with 30 mg THC alone. Other pharmacodynamic effects were unchanged by D-limonene. D-limonene plasma concentrations were dose orderly, and concurrent administration of D-limonene did not alter THC pharmacokinetics. Conclusions: D-limonene selectively attenuated THC-induced anxiogenic effects, suggesting this terpenoid could increase the therapeutic index of THC. Future research should determine whether this effect extends to oral dose formulations and evaluate the interactions between other cannabis terpenoids or cannabinoids and THC.
KW - Anxiety
KW - Cannabis
KW - D-limonene
KW - THC
UR - http://www.scopus.com/inward/record.url?scp=85187975375&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85187975375&partnerID=8YFLogxK
U2 - 10.1016/j.drugalcdep.2024.111267
DO - 10.1016/j.drugalcdep.2024.111267
M3 - Article
C2 - 38498958
AN - SCOPUS:85187975375
SN - 0376-8716
VL - 257
JO - Drug and alcohol dependence
JF - Drug and alcohol dependence
M1 - 111267
ER -